Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
- 27 May 1999
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (21), 1605-1613
- https://doi.org/10.1056/nejm199905273402101
Abstract
In patients infected with human immunodeficiency virus type 1 (HIV-1), combination antiretroviral therapy can result in sustained suppression of plasma levels of the virus. However, replication-competent virus can still be recovered from latently infected resting memory CD4 lymphocytes; this finding raises serious doubts about whether antiviral treatment can eradicate HIV-1.Keywords
This publication has 25 references indexed in Scilit:
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Turnover of naive- and memory-phenotype T cells.The Journal of Experimental Medicine, 1994
- Genotypic and Phenotypic Characterization of HIV-1 Patients with Primary InfectionScience, 1993
- Lifespan of human lymphocyte subsets defined by CD45 isoformsNature, 1992
- PHYLOGENIES FROM MOLECULAR SEQUENCES: INFERENCE AND RELIABILITYAnnual Review of Genetics, 1988